Medtronic received information via literature regarding late incidence and determinants of stroke after aortic and mitral valve replacement.All data were collected from a single center between 1970 and 2002.The overall study population included 3,189 patients (predominantly male, mean age 61.41 years).Among these patients, 1,546 were implanted with a medtronic hall mechanical valve (n=620) or a medtronic hancock i (n=221), hancock ii (n=577), or intact (n=128) bioprosthetic valve.No unique device identifier numbers were provided.Among all patients, 97 deaths occurred due to stroke as a primary cause.No further details were provided on these deaths.Based on the available information medtronic product was not directly associated with the death(s).Among all patients, adverse events included: stroke with neurologic deficit lasting more than three weeks, major bleeding events requiring hospital admission or transfusion.Based on the available information medtronic product may have been associated with the adverse event(s).No additional adverse patient effects or product performance issues were reported.
|